NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARGINIQ is a fixed-dose combination extended-release oral tablet containing oxycodone hydrochloride (an opioid analgesic) and naloxone hydrochloride (an opioid antagonist). It is indicated for the management of moderate to severe chronic pain requiring continuous opioid therapy. The naloxone component is designed to deter opioid abuse by blocking euphoric effects if the tablet is tampered with or injected.
Peak
TARGINIQ is at peak lifecycle stage with moderate competitive pressure (30/100), indicating stable but defended market position that may sustain mid-sized brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TARGINIQ roles center on defending market share in a mature, competitive pain management category with significant regulatory scrutiny around opioid products. Career growth is limited to optimization of existing commercial infrastructure rather than new market expansion.
Brand ManagerField Sales Representative
Worked on TARGINIQ at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.